Prognosis for women with breast cancer not worse for those with family history
the ONA take:
A family history of breast cancer does not influence prognosis for women with breast cancer, according to results of a new large study from UK researchers. Approximately one-quarter of breast cancer cases in developed countries are thought to be hereditary.
The researchers conducted an analysis of the Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) study, which included 2,850 women younger than 41 years with a breast cancer diagnosis and were treated in the United Kingdom.
POSH investigators had recorded information on patients’ tumors, treatment, family history of breast/ovarian cancer, and personal characteristics over a 15-year period.
In this study, no significant differences were found in cancer recurrence rates between women with a family history and those with no family history.
Future investigations will focus on the impact of certain gene variants on the effectiveness of different anticancer treatments.
A family history of breast cancer does not influence prognosis for women with breast cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|